Role of cell surface molecules and autologous ascitic fluid in determining efficiency of adenoviral transduction of ovarian cancer cells

Cancer Gene Therapy

Volumn 17, Issue 10, 2010, Pages 684-693

  Ingram, N ^a   MacCormac, L P ^a   Oxley, N T ^a   Burns, P A ^a   Hall, G D ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

adenovirus; ascitic fluid; CAR; integrin; ovarian cancer; primary cells

Indexed keywords

COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; INTEGRIN;

ADENOVIRUS; ADULT; AGED; ARTICLE; ASCITES FLUID; CELL CULTURE; CELL SURFACE; CLINICAL ARTICLE; GENE THERAPY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOVIRIDAE; AGED; AGED, 80 AND OVER; ASCITIC FLUID; FEMALE; GENE THERAPY; HUMANS; INTEGRIN BETA3; MIDDLE AGED; OVARIAN NEOPLASMS; RECEPTORS, VIRUS; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED;

ADENOVIRIDAE;

EID: 77956870697     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2010.24     Document Type: Article

References (30)

1. Alberts DS, Markman M, Muggia F, Ozols RF, Eldermire E, Bookman MA et al. Proceedings of a GOG workshop on intraperitoneal therapy for ovarian cancer. Gynecol Oncol 2006; 103: 783-792.
2. Alvarez RD, Gomez-Navarro J, Wang M, Barnes MN, Strong TV, Arani RB et al. Adenoviral-mediated suicide gene therapy for ovarian cancer. Mol Ther 2000; 2: 524-530.
3. Buller RE, Runnebaum IB, Karlan BY, Horowitz JA, Shahin M, Buekers T et al. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther 2002; 9: 553-566.
4. Hasenburg A, Tong XW, Rojas-Martinez A, Nyberg- Hoffman C, Kieback CC, Kaplan A et al. Thymidine kinase gene therapy with concomitant topotecan chemotherapy for recurrent ovarian cancer. Cancer Gene Ther 2000; 7: 839-844.
5. Vasey PA, Shulman LN, Campos S, Davis J, Gore M, Johnston S et al. Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol 2002; 20: 1562-1569.
6. Wolf JK, Bodurka DC, Gano JB, Deavers M, Ramondetta L, Ramirez PT et al. A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxelresistant epithelial ovarian cancer. Gynecol Oncol 2004; 94: 442-448.
7. Metcalf KS, Selby PJ, Trejdosiewicz LK, Southgate J. Culture of ascitic ovarian cancer cells as a clinically-relevant ex vivo model for the assessment of biological therapies. Eur J Gynaecol Oncol 1998; 19: 113-119.
8. Provencher DM, Finstad CL, Saigo PE, Rubin SC, Hoskins WJ, Federici MG et al. Comparison of antigen expression on fresh and cultured ascites cells and on solid tumors of patients with epithelial ovarian cancer. Gynecol Oncol 1993; 50: 78-83.
9. Bergelson JM, Krithivas A, Celi L, Droguett G, Horwitz MS, Wickham T et al. The murine CAR homolog is a receptor for coxsackie B viruses and adenoviruses. J Virol 1998; 72: 415-419.
10. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 1993; 73: 309-319.
11. Bruning A, Kohler T, Quist S, Wang-Gohrke S, Moebus VJ, Kreienberg R et al. Adenoviral transduction efficiency of ovarian cancer cells can be limited by loss of integrin beta3 subunit expression and increased by reconstitution of integrin alphavbeta3. Human Gene Ther 2001; 12: 391-399.
12. You Z, Fischer DC, Tong X, Hasenburg A, Aguilar- Cordova E, Kieback DG. Coxsackievirus-adenovirus receptor expression in ovarian cancer cell lines is associated with increased adenovirus transduction efficiency and transgene expression. Cancer Gene Ther 2001; 8: 168-175.
13. Zeimet AG, Muller-Holzner E, Schuler A, Hartung G, Berger J, Hermann M et al. Determination of molecules regulating gene delivery using adenoviral vectors in ovarian carcinomas. Gene Ther 2002; 9: 1093-1100.
14. Hemminki A, Kanerva A, Liu B, Wang M, Alvarez RD, Siegal GP et al. Modulation of coxsackie-adenovirus receptor expression for increased adenoviral transgene expression. Cancer Res 2003; 63: 847-853.
15. Kim M, Zinn KR, Barnett BG, Sumerel LA, Krasnykh V, Curiel DT et al. The therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells. Eur J Cancer 2002; 38: 1917-1926.
16. Dunfield LD, Shepherd TG, Nachtigal MW. Primary culture and mRNA analysis of human ovarian cells. Biol Proced Online 2002; 4: 55-61.
17. Verschraegen CF, Hu W, Du Y, Mendoza J, Early J, Deavers M et al. Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic Mullerian cancers. Clin Cancer Res 2003; 9: 845-852.
18. Blackwell JL, Li H, Gomez-Navarro J, Dmitriev I, Krasnykh V, Richter CA et al. Using a tropism-modified adenoviral vector to circumvent inhibitory factors in ascites fluid. Human Gene Ther 2000; 11: 1657-1669.
19. Ingram N, Porter CD. Transcriptional targeting of acute hypoxia in the tumour stroma is a novel and viable strategy for cancer gene therapy. Gene Ther 2005; 12: 1058-1069.
20. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 2001; 22: 255-288.
21. Jakubczak JL, Rollence ML, Stewart DA, Jafari JD, Von Seggern DJ, Nemerow GR et al. Adenovirus type 5 viral particles pseudotyped with mutagenized fiber proteins show diminished infectivity of coxsackie B-adenovirus receptor-bearing cells. J Virol 2001; 75: 2972-2981.
22. Hemminki A, Wang M, Desmond RA, Strong TV, Alvarez RD, Curiel DT. Serum and ascites neutralizing antibodies in ovarian cancer patients treated with intraperitoneal adenoviral gene therapy. Human Gene Ther 2002; 13: 1505-1514.
23. Cichon G, Boeckh-Herwig S, Kuemin D, Hoffmann C, Schmidt HH, Wehnes E et al. Titer determination of Ad5 in blood: a cautionary note. Gene Ther 2003; 10: 1012-1017.
24. Cohen CJ, Shieh JT, Pickles RJ, Okegawa T, Hsieh JT, Bergelson JM. The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction. Proc Natl Acad Sci USA 2001; 98: 15191-15196.
25. Hasenburg A, Fischer DC, Tong XW, Rojas-Martinez A, Kaufman RH, Ramzy I et al. Adenovirus-mediated thymidine kinase gene therapy for recurrent ovarian cancer: expression of coxsackie-adenovirus receptor and integrins alphavbeta3 and alphavbeta5. J Soc Gynecol Invest 2002; 9: 174-180.
26. Raki M, Särkioja M, Desmond RA, Chen D-T, Bützow R, Hemminki A et al. Oncolytic adenovirus Ad5/3-[Delta]24 and chemotherapy for treatment of orthotopic ovarian cancer. Gynecol Oncol 2008; 108: 166-172.
27. Morrison J, Briggs SS, Green NK, Thoma C, Fisher KD, Kehoe S et al. Cetuximab retargeting of adenovirus via the epidermal growth factor receptor for treatment of intraperitoneal ovarian cancer. Human Gene Ther 2009; 20: 239-251.
28. Jiang E, He X, Chen X, Sun G, Wu H, Wei Y et al. Expression of CD40 in ovarian cancer and adenovirusmediated CD40 ligand therapy on ovarian cancer in vitro. Tumori 2008; 94: 356-361.
29. Wu Y, Li ZY, Zhao X, Kan B, Wei YQ. Inhibition of ovarian tumor growth by gene therapy with recombinant soluble vascular endothelial growth factor receptor 2. Human Gene Ther 2006; 17: 941-948.
30. Waddington SN, McVey JH, Bhella D, Parker AL, Barker K, Atoda H et al. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 2008; 132: 397-409.